×

MSA: THE RESEARCH RADAR

Fall 2024

TRIALS NOW RECRUITING

ION464*

ION464, also known as BIIB101, is an investigational antisense medicine designed to inhibit the production of the alpha-synuclein protein as a potential therapy for a group of neurodegenerative disorders that include Parkinson’s disease (PD) and multiple system atrophy (MSA).

AskBio MSA-101 Trial

 

MSA-101 is a Phase 1 clinical trial evaluating the safety of AAV2-GDNF, a one-time gene therapy for multiple system atrophy (MSA). This therapy delivers GDNF protein directly into the brain to protect neurons and improve symptoms. Participants have a 67% chance of receiving active treatment, while the control group may later access the therapy after the study.

 

Theravance Cypress Phase 3 Clinical Trial

Have you been diagnosed with multiple system atrophy (MSA) and have dizziness symptoms associated with neurogenic orthostatic hypotension (nOH)? If so, you may qualify for the Cypress Study.

Phase 2 Study of ONO-2808

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

A Progression Chart

2022 Research Recap

During the Fourth Annual MSA United Virtual Conference (2023), Professor Robin Wu (Taiwan) offered this chart as a useful explanation of the progressive nature of MSA. The chart was originally developed by Professors Poewe, Stankovic, Halliday, et al. in the journal, Nature Reviews

Disease Primers

Global Research Information Registry

The International Research Information Registry is a way for MSA patients to provide their contact information and other details, if they wish to be contacted about participating in experimental drug trials and research studies.

Defeat MSA Alliance (USA) and its MSA United Consortium partners continue to strongly advocate for more drug trials and a more equitable implementation of them worldwide.

This informational registry is hosted by Defeat MSA Alliance (USA) but available to anyone diagnosed with MSA (or any related disease) globally. It is completely voluntary and strictly confidential.

If you are interested in being contacted about a clinical trail, please click this link to access the information registry. 

Medical Disclaimer

The purpose of this email blast is to provide a report about current MSA clinical trials and convey other research information. It is for informational purposes only. All readers are advised to consult with their health providers before acting on any information in this email.
All the charities affiliated with MSA United Research Consortium are staffed entirely by volunteers – every single donation goes directly into our great cause.

Help Us Defeat MSA Now and Forever!

Defeat MSA Alliance (USA)
29924 Jefferson Ave,
Saint Clair Shores, Michigan
USA
facebook x instagram linkedin youtube
You received this email blast because you subscribed to our newsletter, registered for a conference or submitted an inquiry.
 
If you wish to unsubscribe, please do so, below.